Healthcare
Gerresheimer AG(GRRMF)
Live Price
Offline$32.10
-0.31% today
1Y Change
-40.06%
Window
Jun 25, 2025 → Jun 22, 2026
- Market Cap
- $850.00M
- Revenue Growth
- +2.3%
- EPS Growth
- -8.6%
- Dividend Yield
- 0.2%
Coverage: 234 bars · Jun 25, 2025 → Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Gerresheimer AG (GRRMF) is a Healthcare stock with a market cap of $850.00M and listed on OTC. The stock last traded around $32.10 and down 40.1% across the available one-year price window (Jun 25, 2025 → Jun 22, 2026). Baseline metrics include revenue growth of +2.3%, EPS growth of -8.6%, a dividend yield of 0.2%. What stands out right now is revenue +2.3%, EPS -8.6%, free cash flow -284.3% with operating margin 7.8% and ROIC 2.4%. The dividend is present but secondary, with a yield around 0.2%. Valuation already assumes a fairly strong business story at P/E 36.3 and price/sales 0.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines GRRMF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+2.3% vs +7.6% peer median
Operating Margin
Below sector median
+7.8% vs +19.4% peer median
P/E
Near sector median
36.3 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Jun 10, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +2.3% and EPS is at -8.6%, with operating margin around 7.8%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 0.2%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -3.5% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Δ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Jun 10, 2026 | — | +0.0% | +0.0% | — |
2026 Mar 31, 2026 | — | +0.0% | -6.1% | -6.1% |
2026 Feb 25, 2026 | +0.0% | +0.0% | -4.3% | +9.8% |
Benchmark Edge
GRRMF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
GRRMF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
GRRMF Max Drawdown
-66.23%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for GRRMF and SPY.
Company Overview
Gerresheimer AG
Other OTC
Gerresheimer AG, together with its subsidiaries, manufactures and sells packaging products, and drug delivery-devices and solutions worldwide. It operates through Plastics & Devices, Primary Packaging Glass, and Advanced Technologies divisions. The Plastics & Devices division offers drug delivery systems, including inhalers, insulin pen systems, prefillable syringes, and diagnostic systems for the pharma, biotech, diagnostics, and medical technology industries; containers and closures, PET bottles, eye droppers, nasal sprays, nebulizers, applicators, and accessories for solid, liquid, and ophthalmic applications; and bottles and containers for nutritional supplements. The Primary Packaging Glass division offers glass primary packaging for pharma and cosmetics industries, such as infusion, dropper, and syrup bottles; injection vials, ampoules, and cartridges; miniature bottles and glass containers for liquid food, spices, and spirits; and packaging solutions for fragrances, deodorants, skin care, and wellness products, as well as beauty and pharmaceutical products. The Advanced Technologies division develops smart drug delivery systems, such as micro pumps, which are used to self-administer medication for Parkinson's disease or heart failure to pharmaceutical and biotech customers. The company was founded in 1864 and is headquartered in Düsseldorf, Germany.
- Leadership
- Uwe Ferdinand Röehrhoff
- IPO Date
- Sep 11, 2009
- Employees
- 13.6k
- Street Address
- Klaus-Bungert-Strasse 4
- Mailing
- Düsseldorf, 40468
- Region
- Düsseldorf, DE
- Reporting Currency
- USD
- Investor Line
- 49 211 61 81 00
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 36.3
- EV/EBITDA
- 7.6
- Price/Sales
- 0.4
- Price/Book
- 0.6
Growth
- Revenue
- +2.3%
- EPS
- -8.6%
- Free Cash Flow
- -284.3%
Profitability
- Gross Margin
- 26.9%
- Operating Margin
- 7.8%
- Net Margin
- 1.0%
- ROE
- 1.6%
- ROIC
- 2.4%
Balance Sheet
- Debt/Equity
- 1.65
- Current Ratio
- 0.98
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.